The Mike Slive Foundation has awarded a grant to Ming Chen, PhD to test whether the induction of ferroptosis can help slow the growth of neuroendocrine prostate cancer in preclinical animal models and to determine how it works. The Mike Slive Foundation funds cutting-edge research with a vision to eradicate prostate cancer as a major public health threat in our lifetime. Developing effective targeted therapies for patients with neuroendocrine prostate cancer is an unmet clinical need. This project will take advantage of Dr. Chen’s expertise in genetically engineered mouse models of prostate cancer to test a drug candidate for neuroendocrine prostate cancer.
